Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPS804 safety and pharmacokinetics in late-stage chronic kidney disease (CKD-5D)
2012-003348-63Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of setrusumab in chronic kidney disease (CKD), chronic kidney disease-mineral and bone disorder (CKD-MBD), sponsored by Novartis. Started Oct 2012; status: terminated.
02
Drugs
setrusumab
03
Conditions
chronic kidney disease (CKD)chronic kidney disease-mineral and bone disorder (CKD-MBD)
Beyond the preview
Go deeper on 2012-003348-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003348-63.